Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.85
+0.90 (7.53%)
Apr 28, 2026, 3:12 PM CST
Walvax Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 285.77 | 177.74 | 142.16 | 419.39 | 728.65 | 427.75 |
Depreciation & Amortization | 392.09 | 392.09 | 388.54 | 317.23 | 264.93 | 143.84 |
Other Amortization | 19.67 | 19.67 | 23.02 | 16.1 | 10.57 | 5.71 |
Loss (Gain) From Sale of Assets | -0.08 | -0.08 | 1.77 | 0.83 | 0.38 | -0.23 |
Asset Writedown & Restructuring Costs | 88.25 | 88.25 | 7.68 | 11.31 | 1.66 | 5.11 |
Loss (Gain) From Sale of Investments | -32.23 | -32.23 | 93.31 | 227.64 | 187.54 | 222.86 |
Provision & Write-off of Bad Debts | 148.52 | 148.52 | 64.14 | 39.72 | -1.28 | -4.95 |
Other Operating Activities | -24.19 | -57.6 | 110.72 | 295.46 | 324.44 | 154.22 |
Change in Accounts Receivable | 111.91 | 111.91 | 781.3 | 535.7 | -1,241 | -614.65 |
Change in Inventory | 162.93 | 162.93 | 115.88 | -134.9 | -178.79 | -390.03 |
Change in Accounts Payable | -504.76 | -504.76 | -686.19 | -593.87 | 1,075 | 762.2 |
Operating Cash Flow | 632.36 | 490.93 | 1,037 | 1,134 | 1,201 | 705.28 |
Operating Cash Flow Growth | -33.47% | -52.64% | -8.58% | -5.64% | 70.36% | 517.62% |
Capital Expenditures | -533.99 | -509.54 | -550.03 | -945.52 | -1,091 | -1,103 |
Sale of Property, Plant & Equipment | -0.13 | 0.7 | 0.47 | 0.74 | 0.34 | 3.73 |
Divestitures | - | - | - | 140 | 149.39 | 75.68 |
Investment in Securities | 145.41 | 188.75 | -722 | -10 | - | 41.18 |
Other Investing Activities | 3.44 | 3.44 | 4.9 | 6.78 | 6.26 | 5.74 |
Investing Cash Flow | -385.26 | -316.65 | -1,267 | -807.99 | -935.19 | -977.15 |
Short-Term Debt Issued | - | 144.1 | - | 96.51 | - | - |
Long-Term Debt Issued | - | 159 | 38.22 | 499.31 | 393.82 | 410 |
Total Debt Issued | 1,256 | 303.1 | 38.22 | 595.83 | 393.82 | 410 |
Short-Term Debt Repaid | - | - | -4.6 | -189.19 | - | - |
Long-Term Debt Repaid | - | -407.82 | -353.68 | -78.61 | -405.35 | -149.73 |
Total Debt Repaid | -387.82 | -407.82 | -358.28 | -267.8 | -405.35 | -149.73 |
Net Debt Issued (Repaid) | 867.85 | -104.72 | -320.07 | 328.03 | -11.54 | 260.27 |
Issuance of Common Stock | 2.7 | 2.7 | 0.18 | 36.18 | 397.11 | 1,221 |
Repurchase of Common Stock | - | - | - | -72.21 | -286.42 | - |
Common Dividends Paid | -840.05 | -789.86 | -40.94 | -19.98 | -50.11 | -83.31 |
Other Financing Activities | -2,810 | -1,692 | -10.21 | -35.37 | 45.77 | 338.48 |
Financing Cash Flow | -2,780 | -2,584 | -371.03 | 236.64 | 94.82 | 1,736 |
Foreign Exchange Rate Adjustments | -2.12 | -0.95 | 5.41 | 2.27 | 4.07 | -0.12 |
Net Cash Flow | -2,535 | -2,411 | -595.76 | 564.69 | 365.19 | 1,464 |
Free Cash Flow | 98.37 | -18.62 | 486.49 | 188.25 | 110.31 | -398.21 |
Free Cash Flow Growth | -79.66% | - | 158.43% | 70.65% | - | - |
Free Cash Flow Margin | 4.10% | -0.77% | 17.24% | 4.58% | 2.17% | -11.50% |
Free Cash Flow Per Share | 0.06 | -0.01 | 0.30 | 0.12 | 0.07 | -0.25 |
Cash Income Tax Paid | 142.12 | 131.45 | 136.82 | 264.12 | 309.57 | 244.55 |
Levered Free Cash Flow | -618.98 | -180.28 | 406.85 | 74.57 | -495.85 | -257.05 |
Unlevered Free Cash Flow | -618.41 | -179.71 | 412.12 | 78.29 | -491.4 | -253.44 |
Change in Working Capital | -245.43 | -245.43 | 205.17 | -193.9 | -315.4 | -249.02 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.